@article {Lentini2022.03.26.22272984, author = {Antonio Lentini and Antonio Pereira and Ola Winqvist and Bj{\"o}rn Reinius}, title = {Monitoring of the SARS-CoV-2 Omicron BA.1/BA.2 variant transition in the Swedish population reveals higher viral quantity in BA.2 cases}, elocation-id = {2022.03.26.22272984}, year = {2022}, doi = {10.1101/2022.03.26.22272984}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Throughout the SARS-CoV-2 pandemic, multiple waves of variants of concern have swept across populations, leading to a chain of new and yet more contagious lineages dominating COVID-19 cases. Here, we tracked the remarkably rapid shift from Omicron BA.1 to BA.2 sub-variant dominance in the Swedish population during January{\textendash}March 2022. By analysis of 174,933 clinical nasopharyngeal swab samples using a custom variant-typing RT-PCR assay, we uncover nearly two-fold higher levels of viral RNA in cases with Omicron BA.2. Importantly, increased viral load in the upper pharynx upon BA.2 infection may provide part of the explanation why Omicron BA.2 is more transmissible and currently outcompetes the BA.1 variant across populations.Competing Interest StatementOla Winqvist is a shareholder of ABC Labs where the clinical diagnostics were performed. Bjorn Reinius has worked as a consultant on extraction-free SARS-CoV-2 RT-PCR and is shareholder of GeneBeats, which provides such services.Funding StatementThis research was supported and funded by the SciLifeLab/KAW national COVID-19 research program project grant (2020.0182, 2020.0241, V-2020-0699), the Swedish Research Council (2017-01723) and the Ragnar Soderberg Foundation (M16/17) to BR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical oversight and approval were obtained by the Swedish Ethical Review Authority (Dnr 2020-01945 and 2022-01139-02, Etikprovningsmyndigheten).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://github.com/reiniuslab/OmicronWaves/}, URL = {https://www.medrxiv.org/content/early/2022/03/27/2022.03.26.22272984}, eprint = {https://www.medrxiv.org/content/early/2022/03/27/2022.03.26.22272984.full.pdf}, journal = {medRxiv} }